Please use this identifier to cite or link to this item: https://doi.org/10.3389/fimmu.2018.00416
DC FieldValue
dc.titleCharacterizing the role of monocytes in T cell cancer immunotherapy using a 3d microfluidic model
dc.contributor.authorLee, S.W
dc.contributor.authorAdriani, G
dc.contributor.authorCeccarello, E
dc.contributor.authorPavesi, A
dc.contributor.authorTan, A.T
dc.contributor.authorBertoletti, A
dc.contributor.authorKamm, R.D
dc.contributor.authorWong, S.C
dc.date.accessioned2020-09-01T00:44:49Z
dc.date.available2020-09-01T00:44:49Z
dc.date.issued2018
dc.identifier.citationLee, S.W, Adriani, G, Ceccarello, E, Pavesi, A, Tan, A.T, Bertoletti, A, Kamm, R.D, Wong, S.C (2018). Characterizing the role of monocytes in T cell cancer immunotherapy using a 3d microfluidic model. Frontiers in Immunology 9 (MAR) : 416. ScholarBank@NUS Repository. https://doi.org/10.3389/fimmu.2018.00416
dc.identifier.issn16643224
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/173736
dc.description.abstractIn the hepatitis B virus (HBV)-related hepatocellular carcinoma tumor microenvironment (TME), monocytes reportedly impede natural T cell functions via PD-L1/PD-1 signaling. However, it remains unclear if T cell receptor-redirected T cells (TCR T cells) are similarly inhibited. Hence, we developed a 3D intrahepatic TME microfluidic model to investigate the immunosuppressive potential of monocytes toward HBV-specific TCR T cells and the role of PD-L1/PD-1 signaling. Interestingly, in our 3D static microfluidic model, we observed that monocytes suppressed only retrovirally transduced (Tdx) TCR T cell cytotoxicity toward cancer cells via PD-L1/PD-1, while mRNA electroporated (EP) TCR T cell cytotoxicity was not affected by the presence of monocytes. Importantly, when co-cultured in 2D, both Tdx and EP TCR T cell cytotoxicity toward cancer cells were not suppressed by monocytes, suggesting our 3D model as a superior tool compared to standard 2D assays for predicting TCR T cell efficacy in a preclinical setting, which can thus be used to improve current immunotherapy strategies. © 2018 Lee, Adriani, Ceccarello, Pavesi, Tan, Bertoletti, Kamm and Wong.
dc.sourceUnpaywall 20200831
dc.subjectprogrammed death 1 receptor
dc.subjectT lymphocyte receptor
dc.subjectArticle
dc.subjectcancer immunotherapy
dc.subjectCD8+ T lymphocyte
dc.subjectcell aggregation
dc.subjectcell culture
dc.subjectcell expansion
dc.subjectcell interaction
dc.subjectcell isolation
dc.subjectcontrolled study
dc.subjectcytotoxic T lymphocyte
dc.subjectcytotoxicity assay
dc.subjectelectroporation
dc.subjectflow cytometry
dc.subjecthuman
dc.subjecthuman cell
dc.subjectimmunosuppressive treatment
dc.subjectimpedance
dc.subjectmicrofluidic analysis
dc.subjectmonocyte
dc.subjectperipheral blood mononuclear cell
dc.subjectprotein expression
dc.subjectsignal transduction
dc.subjectT lymphocyte activation
dc.subjectupregulation
dc.typeArticle
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.contributor.departmentMICROBIOLOGY AND IMMUNOLOGY
dc.contributor.departmentPAEDIATRICS
dc.description.doi10.3389/fimmu.2018.00416
dc.description.sourcetitleFrontiers in Immunology
dc.description.volume9
dc.description.issueMAR
dc.description.page416
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3389_fimmu_2018_00416.pdf3.44 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.